TRIUMEQ

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Nigeria, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States

Active ingredients

The drug TRIUMEQ contains a combination of these active pharmaceutical ingredients (APIs):

1 Dolutegravir UNII 1Q1V9V5WYQ - DOLUTEGRAVIR SODIUM

Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral Deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. Read about Dolutegravir

2 Abacavir UNII J220T4J9Q2 - ABACAVIR SULFATE

Abacavir is a NRTI. It is a potent selective inhibitor of HIV-1 and HIV-2. Abacavir is metabolised intracellularly to the active moiety, carbovir 5'-triphosphate (TP). In vitro studies have demonstrated that its mechanism of action in relation to HIV is inhibition of the HIV reverse transcriptase enzyme, an event which results in chain termination and interruption of the viral replication cycle. Read about Abacavir

3 Lamivudine UNII 2T8Q726O95 - LAMIVUDINE

Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Its main mode of action is as a chain terminator of viral reverse transcription. Read about Lamivudine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TRIUMEQ Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AR13		J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AR Antivirals for treatment of HIV infections, combinations
Discover more medicines within J05AR13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10345L
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 510617070057105
Country: CA	Health Products and Food Branch	Identifier(s): 02430932
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 1008-MEE-0515
Country: EE	Ravimiamet	Identifier(s): 1663916, 1663927
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 114940001
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 454381
Country: FR	Base de données publique des médicaments	Identifier(s): 64287253
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 273944
Country: HK	Department of Health Drug Office	Identifier(s): 64012
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7555
Country: IT	Agenzia del Farmaco	Identifier(s): 043618014, 043618026, 043618038
Country: JP	医薬品医療機器総合機構	Identifier(s): 6250106F1021
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1074385, 1074386
Country: NG	Registered Drug Product Database	Identifier(s): B4-8285
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 136034
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 17489
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100325302
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W65274001, W65274002
Country: SG	Health Sciences Authority	Identifier(s): 15100P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699522094561, 8699522094578
Country: US	FDA, National Drug Code	Identifier(s): 49702-231